Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Some of you are trying to reframe this discussion about marginalizing TPL

Noone is against the PTSC BOD, some of us are making the point that we support an effort by our BOD to make moves which increase our authority over MMP related activities. If we achieve that, I'm confident that PDS' Alliasence expenses will decrease, our Licensing communications to infringers will be more credible and therefore more efficient, our Royalty rates can justify an increase, and the excuse for TPL's oversight approval and limited transparency to PTSC and it's Shareholders will be removed.

The BOD and Shareholders are on the same page with regards TPL and Alliasence. Any "inhouse" disagreements we have with the BOD are different, and infact, I fully expect that quite a few of those differences would be eliminated should we gain operational and licensing control of the MMP portfolio. Stockholder value and desirability will only be enhanced.

Share
New Message
Please login to post a reply